CTLA4Ig: bridging the basic immunology with clinical application.
After a very long and windy road, in December of 2005 the FDA approved CTLA4Ig for the treatment of rheumatoid arthritis. Orencia is the first-in-class antagonist of CD28 costimulation. In this perspective, we discuss the science that led to CTLA4Ig development and the clinical challenges in bringing the drug from the bench to the bedside.
Diabetes Center, University of California, San Francisco, San Francisco, California 94143, USA. jbluest@immunetolerance.org
Jeffrey A
JA
Bluestone
E William
EW
St Clair
Laurence A
LA
Turka
D000069594:Abatacept; D000818:Animals; D018106:CD28 Antigens / Q000502:physiology; D023201:CD40 Ligand / Q000502:physiology; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D018106:CD28 Antigens; D018796:Immunoconjugates; D023201:CD40 Ligand; D000069594:Abatacept